Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2024-09-27 Earnings Release
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Earnings Release Classification · 95% confidence The document is explicitly titled '# **Press Release**' and announces a significant corporate event: the US FDA approval of Dupixent for COPD. It contains quotes from CEOs and scientific officers, details clinical trial results (BOREAS and NOTUS), and provides contact information for Media and Investor Relations. This format is characteristic of an initial announcement of financial or material business news, which aligns best with the 'Earnings Release' (ER) category, as it releases key performance/approval information, even though it's not strictly quarterly earnings. Since it is a press release announcing a major regulatory/product milestone, and not a comprehensive report (like 10-K or IR), ER is the most appropriate fit among the provided options for a major, time-sensitive announcement. Q3 2024
2024-09-27 English
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific regulatory event: the approval of Dupixent by the Chinese National Medical Products Administration (NMPA) for COPD treatment. It contains key highlights, quotes from management/doctors, and background information on the drug and the disease. This format is characteristic of an initial announcement of a significant corporate or regulatory event, rather than a comprehensive periodic report (like 10-K or IR) or a transcript. Since it is a press release announcing a regulatory/product milestone, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a formal public announcement that doesn't fit the more specific categories like ER (Earnings Release) or CAP (Financing Update). Given the document length (26,076 chars), it is substantial, but its nature is that of a formal announcement/release.
2024-09-27 French
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Regulatory Filings Classification · 100% confidence The document is explicitly titled '# **Press Release**' and announces a regulatory approval (Dupixent approved in China by the NMPA for COPD). It contains quotes from company executives (Sanofi and Regeneron), clinical trial summaries (BOREAS and NOTUS), and standard sections like 'About COPD', 'About Sanofi and Regeneron's COPD Clinical Research Program', and 'Sanofi forward-looking statements'. This structure is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is a press release announcing a significant event (regulatory approval and associated clinical data) rather than a comprehensive periodic financial report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as these releases often accompany or precede formal earnings reports to disseminate key news. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal regulatory filing like 10-K or AR.
2024-09-27 English
Communiqué de presse : Mise en ligne du document «Q3 2024 Aide mémoire »
Report Publication Announcement Classification · 99% confidence The document is a press release ("Communiqué de presse") announcing the online posting ("Mise en ligne") of a document titled "Q3 2024 Aide mémoire" (Q3 2024 Memo/Aide-mémoire). It explicitly states that this document is intended to assist the financial community in modeling quarterly results and contains details on non-recurring items, currency effects, and share count. Crucially, it mentions that the actual Q3 2024 results will be announced later (October 25, 2024). Since this document is an announcement about the availability of supplementary material related to upcoming financial results, and not the results themselves (ER) or a comprehensive report (IR/10-K), it fits best as a Report Publication Announcement (RPA), as it announces the publication of a supporting document. The document length (5852 chars) is moderate, but the content is purely an announcement of publication, aligning with the RPA definition.
2024-09-26 French
Press Release: Availability of the Q3 2024 Aide mémoire
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "Press Release" and announces the *availability* of the "Q3 2024 Aide mémoire." It states that the actual Q3 2024 results will be published later (October 25, 2024). The document itself is a short announcement providing contact information and boilerplate forward-looking statements, rather than the detailed financial report (IR) or the results announcement (ER). According to Rule #2 (The "MENU VS MEAL" Rule), when a document announces that a report is available or attached, it should be classified as a Report Publication Announcement (RPA).
2024-09-26 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Sanofi, which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. It includes references to press releases attached as exhibits, which are typical for 6-K filings that provide current information but are not comprehensive financial reports. The document length is short (1838 characters), and it mainly announces press releases rather than containing detailed financial statements or management discussion. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a certification or officer attestation. Given the nature of Form 6-K filings as regulatory updates for foreign issuers, the best classification is Regulatory Filings (RNS).
2024-09-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.